Andelyn Biosciences, the US cell and gene therapy CDMO, has announced a new collaboration agreement with with ENCell from South Korea in order to create a strategic manufacturing bridge between the US-APAC regions so as to facilitate the global delivery of gene therapies.
The new partnership leading to global delivery of gene therapies will combine their industry-leading GMO manufacturing facilities and technical expertise as well as regional networks to speed up the development and manufacturing along with global growth of client programmes that bring next-generation gene therapies to patients around the world, the pair said in a statement. The partnership will simplify global expansion by eliminating regulatory and logistical challenges and streamline a dual-hemisphere workflow through connecting US and APAC manufacturing hubs.
Additionally, local manufacturing for clinical trials in-country will make sure regional supply chains can meet the expectations of local patients, minimising waiting times and speeding up commercialisation.
The CEO at Andelyn, Wade Macedone, said, “Our partnership with ENCell is a powerful step forward in Andelyn’s mission to help bring life-saving therapies to patients worldwide. By joining forces with such a respected leader in South Korea, we are not just expanding our global footprint; we are leveraging our unique strengths to deliver a truly seamless international manufacturing network. This collaboration reinforces our shared leadership in the cell and gene therapy space and ensures that, together, we can support our clients with the expertise and scale needed to deliver the next generation of medicines on a global stage.”
ENCell’s CEO, Dr Jong Wook Chang, added that “this partnership with Andelyn represents a significant step in expanding the global CGT ecosystem. By combining Andelyn’s expertise in viral vector development and cGMP manufacturing with ENCell’s clinical and manufacturing capabilities across APAC, we are establishing a seamless manufacturing platform connecting the United States and Asia-Pacific. Together, we will enable more efficient development and scalable production of gene therapies, supporting our clients from early-stage development through global clinical trials and commercialisation.”
